WHAT IS CLAIMED IS:

1. Use of (i) an LHRH agonist or antagonist in association with (ii) a selective estrogen receptor modulator (acolbifene (EM-652·HCl, EM-1538) as example) in the preparation of a medicament for treating or reducing the likelihood of acquiring estrogen-related diseases comprising inhibiting ovarian hormonal secretion in a patient.

2. Use of (i) an LHRH agonist or antagonist in association with (ii) a selective estrogen receptor modulator (acolbifene (EM-652·HCl, EM-1538) as example) and with (iii) a sex steroid precursor or prodrug thereof, or salt of the foregoing compounds in the preparation of a medicament for treating or reducing the likelihood of acquiring estrogen-related diseases comprising inhibiting ovarian hormonal secretion in a patient.

3. The use of claim 1 or 2 wherein said estrogen-related disease is endometriosis.

4. The use of claim 1 or 2 wherein said estrogen-related diseases are uterine fibroids or uterine leiomyomas.

5. The use of claim 1 or 2 wherein said estrogen-related diseases are endometrial cancer, uterine cancer, uterine leiomyosarcomas, ovarian cancer or breast cancer.

6. The use of claim 1 or 2 wherein said estrogen-related diseases are polycystic ovary syndrome, dysfunctional uterine bleeding, vaginal bleeding,

menorrhagia, premenstrual syndrome, migraine headache, cervical intraepithelial neoplasia, adenomyosis or Alzheimer's disease.

7. The use of claim 2 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, androst-5-ene-3β,17β-diol, prodrug thereof, and salt of the foregoing compounds.

8. The use of claim 2 wherein the sex steroid precursor is dehydroepiandrosterone.

9. The use of claim 1 or 2 wherein said patient is a human.

10. A kit comprising a first container containing a therapeutically effective amount of a selective estrogen receptor modulator (acolbifene (EM-652·HCl, EM-1538) as example) and further comprising a second container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist.

11. A kit comprising a first container containing a pharmaceutical formulation comprising a therapeutically effective amount of a selective estrogen receptor modulator (acolbifene (EM-652·HCl, EM-1538) as example) and a therapeutically effective amount of at least one sex steroid precursor or prodrug thereof or salt of the foregoing compounds, and further comprising a second container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist.

12. A kit comprising a first container containing a therapeutically effective amount of a selective estrogen receptor modulator (acolbifene (EM-652·HCl,

EM-1538) as example), a second container containing a therapeutically effective amount of at least one sex steroid precursor or prodrug thereof or salt of the foregoing compounds, and further comprising a third container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist.

13. The kit of any one of claims 11 and 12 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, 4-androstene-3,17-dione, androst-5-ene-3β,17β-diol, prodrug thereof, and salt of the foregoing compounds.

14. The kit of any one of claims 11 and 12 wherein the sex steroid precursor is dehydroepiandrosterone.

15. The kit of claim 10 for use of any one of claims 1, 19 and 20.

16. The kit of any one of claims 11 and 12 for use of any one of claims 2, 21 and 22.

17. The kit of claim 11 wherein the pharmaceutical formulation is selected from the group consisting of pill, capsule, tablet, cream, gel, intravaginal suppository and intravaginal ovule.

18. The use of claim 2 or kit of any one of claims 11 and 12 wherein said selective estrogen receptor modulator is Acolbifene (EM-652·HCl, EM-1538) and where said sex steroid precursor is dehydroepiandrosterone.

19. Use of (i) an LHRH agonist or antagonist in association with (ii) a

selective estrogen receptor modulator, namely Acolbifene (EM-652·HCl, EM-1538) in the preparation of a medicament for treating or reducing the likelihood of acquiring endometriosis in a woman.

20. Use of (i) an LHRH agonist or antagonist in association with (ii) a selective estrogen receptor modulator, namely Acolbifene (EM-652·HCl, EM-1538) in the preparation of a medicament for treating or reducing the likelihood of acquiring uterine fibroids or uterine leiomyomas in a woman.

21. Use of (i) an LHRH agonist or antagonist in association with (ii) a selective estrogen receptor modulator, namely Acolbifene (EM-652·HCl, EM-1538) and with (iii) a sex steroid precursor, namely dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring endometriosis in a woman.

22. Use of (i) an LHRH agonist or antagonist in association with (ii) a selective estrogen receptor modulator, namely Acolbifene (EM-652·HCl, EM-1538) and with (iii) a sex steroid precursor, namely dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring uterine fibroids or uterine leiomyomas in a woman.

23. The use of any one of claims 1, 2, 19, 20, 21 and 22 wherein the selective estrogen receptor modulator has no estrogenic activity on breast, uterine or endometrial tissues.

WHAT IS CLAIMED IS:

1 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) in the preparation of a medicament for treating or reducing the likelihood of acquiring estrogen-related diseases comprising inhibiting ovarian hormonal secretion in a patient.

2 Use of (i) an LHRH agonist or antagonist in association with (ii) a selective estrogen receptor modulator and with (iii) a sex steroid precursor or prodrug thereof, or salt of the foregoing compounds in the preparation of a medicament for treating or reducing the likelihood of acquiring estrogen-related diseases comprising inhibiting ovarian hormonal secretion in a patient.

3 The use of claim 2 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

4 The use of claim 1 or 2 wherein said estrogen- related disease is endometriosis.

5 The use of claim 1 or 2 wherein said estrogen-related diseases are uterine fibroids or uterine leiomyomas.

6 The use of claim 1 or 2 wherein said estrogen-related diseases are endometrial cancer, uterine cancer, uterine leiomyosarcomas, ovarian cancer or breast cancer.

7 The use of claim 1 or 2 wherein said estrogen-related diseases are polycystic ovary syndrome, dysfunctional uterine bleeding, vaginal bleeding, menorrhagia, premenstrual syndrome, migraine headache, cervical intraepithelial neoplasia or adenomyosis.

8 The use of claim 2 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulphate, 4-androstene-3,17-dione, androst-5-ene-3ß,17ß-diol, prodrug thereof, or salt of the foregoing compounds.

9 The use of claim 2 wherein the sex steroid precursor is dehydroepiandrosterone.

10 The use of claim 1 or 2 wherein said patient is a human.

11 A kit comprising a first container containing a therapeutically effective amount of the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and further comprising a second container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist, when used in the use of any one of claims 1, 4-7, 10 and 20-21.

12 A kit comprising a first container containing a pharmaceutical formulation comprising a therapeutically effective amount of a selective estrogen receptor modulator and a therapeutically effective amount of at least one sex steroid precursor or prodrug thereof or salt of the foregoing compounds, and further comprising a second container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist, when used in the use of any one of claims 2-10 and 22-23.

13 The kit of claim 12 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

14 A kit comprising a first container containing a therapeutically effective amount of a selective estrogen receptor modulator, a second container containing a therapeutically effective amount of at least one sex steroid precursor or prodrug thereof or salt of the foregoing compounds, and further comprising a third container containing a therapeutically effective amount of at least one LHRH agonist or LHRH antagonist, when used in the use of any one of claims 2-10 and 22-23.

15 The kit of claim 14 wherein the selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538).

16 The kit of any one of claims 12-15 wherein the sex steroid precursor is selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulphate, 4-androstene-3,17-dione, androst-5-ene- 3ß,17ß-diol, prodrug thereof, or salt of the foregoing compounds.

17 The kit of any one of claims 12-15 wherein the sex steroid precursor is dehydroepiandrosterone.

18 The kit of claim 12 wherein the pharmaceutical formulation is selected from the group consisting of pill, capsule, tablet, cream, gel, intravaginal suppository and intravaginal ovule.

19 The use of claim 2 or kit of claim 12 or 14 wherein said selective estrogen receptor modulator is acolbifene (EM-652·HCl, EM-1538) and where said sex steroid precursor is dehydroepiandrosterone.

20 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) in the preparation of a medicament for treating or reducing the likelihood of acquiring endometriosis in a woman.

21 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) in the preparation of a medicament for treating or reducing the likelihood of acquiring uterine fibroids or uterine leiomyomas in a woman.

22 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and with (iii) the sex steroid precursor dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring endometriosis in a woman.

23 Use of (i) an LHRH agonist or antagonist in association with (ii) the selective estrogen receptor modulator acolbifene (EM-652·HCl, EM-1538) and with (iii) the sex steroid precursor dehydroepiandrosterone in the preparation of a medicament for treating or reducing the likelihood of acquiring uterine fibroids or uterine leiomyomas in a woman.

24 The use of any one of claims 1, 2 and 20-23 wherein the selective estrogen receptor modulator has no estrogenic activity on breast, uterine or endometrial tissues.